ABC Farmaceutici S.p.A.
Corso Vittorio Emanuele II, 72
10121 Torino (TO)
Contact: Paola Di Domenico
Role: Management
Email: paola.didomenico@abcfarmaceutici.it
Phone: +39 0125 240 111
Website http://www.abcfarmaceutici.it/
Establishment year: 1925
Number of employees: 100
Number of employees R&D: 4
Business sectors: Pharma / Biopharma
Keywords:
pharmaceutical, gastroenterological, pneumological, contract manufacturing, R&D, Xanthine derivative, formulations.
DESCRIPTION
ABC is an Italian pharmaceutical group founded in 1925, engaged in the research, development, production and marketing of pharmaceutical products and active ingredients. The company has obtained numerous international patents in the field of gastroenterology and pneumology thanks to its commitment to more than 90 years of research.
As for industrial development, ABC Farmaceutici is present with state-of-the-art production facilities for the production of pharmaceutical products and active ingredients.
In fact, the company follows the entire supply chain of the drug, from the active ingredient to the manufacture of the finished product, up to their promotion and sale.
The production plants are located in northern Italy: the plant of San Bernardo d’Ivrea (Turin), modern example of high technology in the field of pharmaceutical production, and the plant of Trecate (Novara) for the production of the active ingredient. For the ABC group, these constitute a reliable industrial support for the development of new molecules.
Ethics, competence and experience have allowed ABC Farmaceutici to become a partner of the main pharmaceutical multinational also in the production of finished dosage forms.
WHAT WE OFFER – CONTRACT PRODUCTION,/ LICENSING OPPORTUNITIES
The industrial development achieved in 90 years of activity, has allowed the company to collaborate with leading multinational pharmaceutical companies, for the production of active ingredients and medicines. The contract manufacturing division of ABC Pharmaceuticals is dedicated to the production and development of medicines.
RESEARCH AND DEVELOPMENT
Considerable investments were made in the Research and Development Department, which represents the company’s real human and technological heritage.
ABC’s R&D Centre has developed many molecules still on the market such as Doxofillin, a patented derivative of Xanthine, leader in Italy in the field of pneumology, marketed under the brand ANSIMAR. In 2014, Doxophylline was awarded the title of orphan drug in the United States, for the treatment of bronchiectasis.
At the same time, together with the activity in the field of pure research, ABC Pharmaceuticals has always given special attention to drug development for third parties.
The new R&D activity of ABC, created in 2002, is active in the development of formulations and processes, industrial scale-up, analytical development studies, stability studies (according to ICH guidelines), validation processes, preparation and revision of clinical dossier-chemical-pharmaceutical (in EU CTD format), clinical trials. ABC Research and Development has developed and manufactured many pharmaceutical molecules and formulations on the market and is now active in an important project for the next period.
